This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of Centanafadine, a medication currently in development by Otsuka that for the treatment of ADHD
Ticker(s): OTSKYWho's the expert?
Institution: Alexian Brothers Behavioral Health Hospital and ADHD Clinic
- Child and adolescent psychiatrist in private practice, psychiatric consultant to a number of community clinics, and clinical director of Alexian Brother Behavioral Health Hospital ADHD clinic.
- Treats > 200 patients with ADHD and Board Certified in Psychiatry.
- Member of American Academy of Child & Adolescent Psychiatry and national speaker and leader for pharmaceutical industry concerning ADHD and child/adolescent mood disorders/anxiety.
Interview GoalThis interview will focus on Otsuka Pharmaceutical's recent announcement of positive results from two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD).
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
